Overview
Regeneron Pharmaceuticals is a biotechnology company in Tarrytown, New York, that discovers, develops, manufactures and commercialises medicines including Dupixent, Eylea, Kevzara, Evkeeza and Inmazeb.[2] It uses its proprietary VelociSuite technologies, including VelocImmune genetically humanised mice, to produce fully human and bispecific antibodies.[2] Forbes records sales of US$14.9bn, up 5.1%, and profit of US$4.4bn, a margin near 30%.[2] Regeneron moved from twenty-second to twenty-first place, overtaking Viatris. Forbes records its founding on 8 January 1988 and counts 15,410 employees, with a market value of US$73.2bn, more than CSL, Teva or Viatris.[2]
Regeneron Pharmaceuticals strengths and limitations
Strengths
- Profit margin near 30%
- Proprietary antibody discovery platform
- Higher market value than larger rivals
Limitations
- Dependent on a few brands
- Sales growth of 5.1% is below the sector's leaders
- Smaller scale than the diversified groups
Appears in
Regeneron Pharmaceuticals peers and competitors
Companies ranked in the same lists as Regeneron Pharmaceuticals.
Johnson & Johnson- Amgen
Daiichi Sankyo- Astellas Pharma
Viatris- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Gilead Sciences
Takeda Pharmaceutical
GSK plc
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.